Scholars@Duke
construction release_alert
Profile editing is temporarily unavailable from June 11-24, 2026 while manual profile data entry transitions to Elements. Learn More.
cancel
Jeffrey Crawford

Jeffrey Crawford

George Barth Geller Distinguished Professor for Research in Cancer
Medicine, Medical Oncology
jeffrey.a.crawford@duke.edu
Duke Box 3476, Durham, NC 27710
25177 Morris Bldg, Durham, NC 27710

Selected Publications

Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.

Journal Article Future Oncol · April 2026 Immunotherapy resistance represents a major unmet clinical need for patients with metastatic non-small cell lung cancer (NSCLC). Preclinical studies have identified PCSK9 as an immunosuppressive regulator of antigen presentation, providing a compelling rat ... Full text Link to item Cite

A Two-Stage Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Ec-18 in Altering the Severity and Course of Oral Mucositis Secondary to Chemoradiation Therapy for Squamous Cell Cancers of the Head and Neck.

Journal Article Cancers (Basel) · May 14, 2025 BACKGROUND: Oral mucositis (OM) remains a significant toxicity of concomitant chemoradiation (CRT) for head and neck cancer (HNC). This trial assessed the safety and efficacy of EC-18, an innate immune response mitigator, in attenuating severe OM (SOM) in ... Full text Link to item Cite

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.

Journal Article J Immunother Cancer · February 4, 2025 BACKGROUND: Our study was designed to determine the safety, efficacy, and immunological effects of perioperative pembrolizumab in early-stage NSCLC. METHODS: This is a single-arm phase II study of perioperative pembrolizumab in patients with untreated, cli ... Full text Link to item Cite

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.

Journal Article Nat Commun · January 2, 2025 GT103 is a first-in-class, fully human, IgG3 monoclonal antibody targeting complement factor H that kills tumor cells and promotes anti-cancer immunity in preclinical models. We conducted a first-in-human phase 1b study dose escalation trial of GT103 in re ... Full text Open Access Link to item Cite

Ponsegromab for the Treatment of Cancer Cachexia.

Journal Article N Engl J Med · December 19, 2024 BACKGROUND: Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer cachexia. In a small, open-label, phase 1b stud ... Full text Link to item Cite

The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review.

Conference J Cachexia Sarcopenia Muscle · October 2024 Cancer-associated cachexia is a multifactorial wasting disorder characterized by anorexia, unintentional weight loss (skeletal muscle mass with or without loss of fat mass), progressive functional impairment, and poor prognosis. This systematic literature ... Full text Link to item Cite

Mortality burden of pre-treatment weight loss in patients with non-small-cell lung cancer: A systematic literature review and meta-analysis.

Journal Article J Cachexia Sarcopenia Muscle · August 2024 Cachexia, with weight loss (WL) as a major component, is highly prevalent in patients with cancer and indicates a poor prognosis. The primary objective of this study was to conduct a meta-analysis to estimate the risk of mortality associated with cachexia ... Full text Link to item Cite

Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design.

Journal Article J Cachexia Sarcopenia Muscle · June 2024 BACKGROUND: Cancer cachexia is a multifactorial metabolic wasting syndrome characterized by anorexia, unintentional loss of weight involving both skeletal muscle and adipose tissues, progressive functional impairment and reduced survival. Therapeutic strat ... Full text Link to item Cite

A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia.

Journal Article Clin Cancer Res · February 1, 2024 PURPOSE: Cachexia is common in patients with advanced cancer and is associated with elevated serum growth differentiation factor 15 (GDF-15) concentrations. This first-in-patient (phase Ib), 24-week study assessed use of ponsegromab, a mAb against GDF-15, ... Full text Link to item Cite

The impact of myelosuppression on quality of life of patients treated with chemotherapy.

Journal Article Future Oncol · 2024 Side effects from chemotherapy-induced myelosuppression can negatively affect patients' quality of life (QoL). Neutropenia increases infection risk, and anemia frequently results in debilitating fatigue. Additionally, the bleeding risk associated with thro ... Full text Link to item Cite

On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status.

Journal Article Cancer Treat Res Commun · 2024 INTRODUCTION: Myelosuppression, a challenge in cancer treatment, often results in severe complications. Prophylactic granulocyte colony-stimulating factors, particularly pegfilgrastim, mitigate chemotherapy-induced neutropenia. This narrative review evalua ... Full text Link to item Cite

Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.

Journal Article N Engl J Med · November 2, 2023 BACKGROUND: Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Perioperative regimens may combine benefits of both to improve long-term outcomes. METHODS: We randomly assigned patients ... Full text Link to item Cite

The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps.

Journal Article Curr Opin Oncol · July 1, 2023 PURPOSE OF REVIEW: While chemotherapy treatment options for patients with solid and hematologic malignancies have dramatically improved over recent years, chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) remain major barriers to deliveri ... Full text Link to item Cite

Adapting to Change: A Thoracic Oncology Team's Perspective.

Journal Article JCO Oncol Pract · July 2023 With targeted therapies, outcomes for patients with NSCLC are improving, but better monitoring for AEs is needed. ... Full text Link to item Cite

Factors Associated With Receipt of Molecular Testing and its Impact on Time to Initial Systemic Therapy in Metastatic Non-Small Cell Lung Cancer.

Journal Article Clin Lung Cancer · June 2023 BACKGROUND: Despite recommendations for molecular testing irrespective of patient characteristics, differences exist in receipt of molecular testing for oncogenic drivers amongst metastatic non-small cell lung cancer (mNSCLC) patients. Exploration into the ... Full text Link to item Cite

Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC).

Conference Journal of Clinical Oncology · June 1, 2023 9128 Background: GT103 is a first-in-class IgG3 monoclonal antibody that was derived from a single human B cell and inhibits complement factor H (CFH). CFH is implicated in cancer immune evasion and overexpression portends a poor ... Full text Cite

The mortality burden of cachexia in patients with non-small cell lung cancer: A meta-analysis.

Conference Journal of Clinical Oncology · June 1, 2023 e24075 Background: Cachexia and weight loss have been linked to poor outcomes in patients with cancer. This study’s aim was to conduct a meta-analysis to estimate the risk of mortality associated with cachexia in patients with no ... Full text Cite

Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia.

Conference Journal of Clinical Oncology · June 1, 2023 TPS12147 Background: Cancer cachexia is a multifactorial metabolic syndrome of wasting characterized by anorexia, unintended weight loss, and decreased skeletal muscle mass, leading to progressive functional impairment, fatigue, ... Full text Cite

Two decades of pegfilgrastim: what have we learned? Where do we go from here?

Journal Article Curr Med Res Opin · May 2023 Chemotherapy-induced febrile neutropenia (FN) is a medical emergency that may occur in patients with malignancies receiving myelosuppressive chemotherapy. FN requires early therapeutic intervention since it is associated with increased hospitalizations and ... Full text Link to item Cite

Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.

Journal Article J Natl Cancer Inst · April 11, 2023 BACKGROUND: An important issue for patients with cancer treated with novel therapeutics is how they weigh the effects of treatment on survival and quality of life (QOL). We compared QOL in patients enrolled to SWOG S1400I, a substudy of the LungMAP biomark ... Full text Link to item Cite

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations.

Journal Article ESMO Open · April 2023 BACKGROUND: For patients with stage IV non-small-cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions and exon 21 L858R mutations, osimertinib is the standard of care. Investigating the activity and safety of osimertinib in patie ... Full text Link to item Cite

Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study.

Journal Article Lung Cancer · January 2023 OBJECTIVES: There are limited real-world data about patient-reported outcomes with immunotherapies (IO) in metastatic non-small cell lung cancer (mNSCLC). We describe patient-reported distress and clinical outcomes with IO-based treatments or cytotoxic che ... Full text Link to item Cite

Associations between body mass index, weight loss and overall survival in patients with advanced lung cancer.

Journal Article J Cachexia Sarcopenia Muscle · December 2022 BACKGROUND: Weight loss (WL) has been associated with shorter survival in patients with advanced cancer, while obesity has been associated with longer survival. Integrating body mass index (BMI) and WL provides a powerful prognostic tool but has not been w ... Full text Open Access Link to item Cite

An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD.

Journal Article J Comp Eff Res · December 2022 Aim: Stakeholder engagement is central to comparative effectiveness research yet there are gaps in definitions of success. We used a framework developed by Lavallee et al. defining effective engagement criteria to evaluate stakeholder engagement during a p ... Full text Link to item Cite

A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.

Journal Article Support Care Cancer · October 2022 PURPOSE: We evaluated the incidence of febrile neutropenia (FN) and related clinical outcomes among patients treated with myelosuppressive chemotherapy for nonmyeloid malignancies who received pegfilgrastim on-body injector (OBI) or other options (Other) f ... Full text Link to item Cite

Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?

Journal Article Oncologist · August 5, 2022 Neutropenia and febrile neutropenia (FN) are common complications of myelosuppressive chemotherapy. This review provides an up-to-date assessment of the patient and cost burden of chemotherapy-induced neutropenia/FN in the US, and summarizes recommendation ... Full text Link to item Cite

A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.

Journal Article Support Care Cancer · July 2022 BACKGROUND: Breast cancer chemotherapy often carries a high risk of febrile neutropenia (FN); guidelines recommend prophylaxis with granulocyte colony-stimulating factor (G-CSF), such as pegfilgrastim. Neulasta® Onpro® on-body injector (OBI) is a delivery ... Full text Link to item Cite

A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial.

Journal Article JTO Clin Res Rep · June 2022 INTRODUCTION: Most patients with advanced NSCLC will experience disease progression and death within 2 years. Novel approaches are needed to improve outcomes. METHODS: We conducted an open-label, nonrandomized, phase 2 trial in patients with treatment-naiv ... Full text Link to item Cite

Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-Analysis.

Journal Article Oncologist · September 2021 BACKGROUND: Chemotherapy-induced toxicities lead to therapy dose reduction or delay, affecting patient outcomes. This systematic review and meta-analysis evaluated the impact of relative dose intensity (RDI) on survival in adult patients with solid tumor c ... Full text Link to item Cite

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).

Journal Article J Immunother Cancer · August 2021 INTRODUCTION: S1400F is a non-match substudy of Lung Cancer Master Protocol (Lung-MAP) evaluating the immunotherapy combination of durvalumab and tremelimumab to overcome resistance to anti-programmed death ligand 1 (PD-(L)1) therapy in patients with advan ... Full text Link to item Cite

Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung.

Journal Article Clin Lung Cancer · July 2021 BACKGROUND: Non-small cell lung cancer (NSCLC) is responsible for the most cancer-related deaths in the United States. A better understanding of treatment-related disparities and ways to address them are important to improving survival for patients with me ... Full text Link to item Cite

Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.

Journal Article BMC Cancer · May 27, 2021 BACKGROUND: Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), is commonly used to prevent febrile neutropenia (FN), a potentially life-threatening complication, following myelosuppressive chemotherapy. The FDA label for pegfilgras ... Full text Link to item Cite

Role of dietary carbohydrates on risk of lung cancer.

Journal Article Lung Cancer · May 2021 OBJECTIVES: Inconsistent findings have been reported on the link between dietary carbohydrates and lung cancer. This study aims to comprehensively evaluate the role of dietary carbohydrates on lung cancer risk. MATERIALS AND METHODS: The prospective study ... Full text Link to item Cite

Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation.

Journal Article Oncologist · March 2021 BACKGROUND: Thousands of patients annually receive treatment for advanced non-small cell lung cancer (NSCLC), but little is known about their views on the decision to receive that treatment, or regret. This trial prospectively evaluated the incidence of re ... Full text Link to item Cite

RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry.

Journal Article Lung Cancer · March 2021 OBJECTIVES: Despite disparities in lung cancer incidence and mortality, the molecular landscape of lung cancer in patients of African ancestry remains underexplored, and race-related differences in RNA splicing remain unexplored. MATERIALS AND METHODS: We ... Full text Link to item Cite

Cancer Patients' Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life.

Journal Article Patient Prefer Adherence · 2021 PURPOSE: To evaluate which side effects of chemotherapy are considered most burdensome by patients with cancer, identify which health care professionals pay most attention to symptoms associated with chemotherapy-induced myelosuppression (CIM) from the pat ... Full text Link to item Cite

Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage.

Journal Article Cancer Treat Res Commun · 2021 Evidence-based US guidelines provide recommendations for the use of granulocyte colony-stimulating factor (G-CSF) as supportive therapy in patients with cancer receiving chemotherapy. Pegfilgrastim is recommended for FN prophylaxis in patients with non-mye ... Full text Link to item Cite

Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.

Journal Article J Thorac Oncol · October 2020 INTRODUCTION: Approximately 4% of NSCLC harbor BRAF mutations, and approximately 50% of these are non-V600 mutations. Treatment of tumors harboring non-V600 mutations is challenging because of functional heterogeneity and lack of knowledge regarding their ... Full text Link to item Cite

Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors.

Journal Article Adv Ther · August 2020 INTRODUCTION: Chemotherapy-induced myelosuppression (CIM) is one of the most common dose-limiting complications of cancer treatment, and is associated with a range of debilitating symptoms that can significantly impact patients' quality of life. The purpos ... Full text Open Access Link to item Cite

Abstract B071: Genomic differences between non-small cell lung cancer (NSCLC) in African American and white patients

Conference Cancer Epidemiology, Biomarkers & Prevention · June 1, 2020 AbstractBackground: Racial disparities in lung cancer exist, as African Americans (AAs) have the highest incidence of lung cancer and rate of lung cancer-related death and develop lung cancer at an earlier a ... Full text Cite

Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.

Journal Article J Thorac Oncol · April 2020 INTRODUCTION: Osimertinib has shown promising activity in patients with leptomeningeal metastases (LMs) of EGFR-positive NSCLC at 160 mg once daily (qd) (BLOOM; NCT02228369). We report LM activity with osimertinib (80 mg qd) in a retrospective analysis of ... Full text Link to item Cite

Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer.

Journal Article Lung Cancer · March 2020 OBJECTIVES: Neutropenia is associated with the risk of life-threatening infections, chemotherapy dose reductions and delays that may compromise outcomes. This analysis was conducted to develop a prediction model for chemotherapy-induced severe neutropenia ... Full text Link to item Cite

Abstract OT1-05-01: The incidence of febrile neutropenia (FN) for chemotherapy patients receiving pegfilgrastim by an on-body injector (pegfilgrastim OBI) versus other FN prophylaxis strategies

Conference Cancer Research · February 15, 2020 AbstractFor safety reasons, pegfilgrastim should be administered the day after chemotherapy for prophylaxis of chemotherapy-induced FN (Lyman et al, Cancer. 2017;25:2619-2629). Because this is inconvenient, ... Full text Cite

Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer.

Conference Support Care Cancer · February 2020 PURPOSE: The effects of chemotherapy dose intensity on survival in patients with advanced non-small-cell lung cancer (NSCLC) are poorly understood. We retrospectively analyzed dose delays/reduction, relative dose intensity (RDI), and the association betwee ... Full text Link to item Cite

SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).

Journal Article J Thorac Oncol · October 2019 BACKGROUND: S1400B is a biomarker-driven Lung-MAP substudy evaluating the phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (GDC-0032) in patients with PI3K pathway-activated squamous NSCLC (sqNSCLC). METHODS: Eligible patients had tumoral phosphati ... Full text Link to item Cite

Sarcopenia: A Time for Action. An SCWD Position Paper.

Journal Article J Cachexia Sarcopenia Muscle · October 2019 The term sarcopenia was introduced in 1988. The original definition was a "muscle loss" of the appendicular muscle mass in the older people as measured by dual energy x-ray absorptiometry (DXA). In 2010, the definition was altered to be low muscle mass tog ... Full text Open Access Link to item Cite

Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study.

Journal Article Transl Lung Cancer Res · June 2019 BACKGROUND: Data describing therapeutic outcomes in patients with non-small cell lung cancers (NSCLC) with BRAF mutations remains limited. METHODS: We conducted a retrospective cohort study of 31 patients with metastatic NSCLC treated at Duke University Ho ... Full text Open Access Link to item Cite

Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC.

Conference Journal of Clinical Oncology · May 20, 2019 3102 Background: BRAF alterations (alts) account for ~4% of non-small cell lung cancers (NSCLC) with 50% being non-V600 alts. Because these alts are functionally heterogeneous and have a poorly characterized genomic landscape, de ... Full text Cite

What are the criteria for response to cachexia treatment?

Journal Article Ann Palliat Med · January 2019 The treatment of cancer cachexia remains an unmet medical need. One of the barriers to the development and approval of effective interventions has been the lack of agreement on the proper endpoints for study. The international consensus definition of cance ... Full text Link to item Cite

Disorders of Blood Cell Production in Clinical Oncology

Chapter · January 1, 2019 Management of hematologic abnormalities in cancer pose tremendous challenges in the care of patients. Clinically significant anemia, thrombocytopenia, and neutropenia can limit the ability to treat the malignancy effectively and can profoundly impact patie ... Full text Cite

Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States.

Journal Article J Thorac Oncol · December 2018 INTRODUCTION: Although metastatic NSCLC is widely treated in both academic centers (ACs) and community-based centers (CCs), it is unclear whether outcomes are similar across both settings. A growing variety of chemotherapies and targeted agents for an incr ... Full text Link to item Cite

Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC

Journal Article Annals of oncology : official journal of the European Society for Medical Oncology · November 1, 2018 Full text Cite

Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer.

Journal Article Clin Breast Cancer · October 2018 BACKGROUND: The effects of chemotherapy dose intensity on patient outcomes in advanced cancer are not well understood. We studied the association between chemotherapy relative dose intensity (RDI) and overall survival (OS) among patients with advanced brea ... Full text Link to item Cite

Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy.

Journal Article J Thorac Oncol · September 2018 INTRODUCTION: Muscle wasting has detrimental effects, including increased mortality. Identifying patients at risk can guide treatment efforts. METHODS: POWER 1 and 2 were randomized, double-blind, placebo-controlled, multinational phase III trials that stu ... Full text Link to item Cite

A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia.

Journal Article Crit Rev Oncol Hematol · September 2018 Erythropoiesis-stimulating agents (ESAs) are man-made forms of erythropoietin used in the treatment of anemia. This quick-scoping review of systematic literature reviews (SLRs) was conducted to define the clinical, economic, and health-related quality of l ... Full text Link to item Cite

A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.

Journal Article Oncologist · July 2018 PURPOSE: This study evaluated the maximum tolerated dose or recommended phase II dose (RPTD) and safety and tolerability of the ganitumab and everolimus doublet regimen followed by the ganitumab, everolimus, and panitumumab triplet regimen. MATERIALS AND M ... Full text Link to item Cite

Immune checkpoint inhibition

Chapter · June 27, 2018 Immune checkpoint inhibitors (ICI) represent a class of immuno-oncology drugs consisting of monoclonal antibodies occurring against inhibitory receptors or ligands within the immune system including CTLA-4, PD-1, and PD-L1. ICI has transformed oncology in ... Full text Cite

Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia.

Conference Clin Lung Cancer · March 2018 Lung cancer, compared with other solid tumors, is associated with high mortality rates from febrile neutropenia. The risk factors associated with in-hospital mortality were identified and compared for patients with lung cancer and patients with other solid ... Full text Link to item Cite

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.

Journal Article Support Care Cancer · January 2018 PURPOSE: Filgrastim (NEUPOGEN®) is the originator recombinant human granulocyte colony-stimulating factor widely used for preventing neutropenia-related infections and mobilizing hematopoietic stem cells. This report presents findings of a systematic liter ... Full text Link to item Cite

Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.

Journal Article Clin Cancer Res · December 15, 2017 Purpose: To determine the immunologic effects of neoadjuvant chemotherapy plus ipilimumab in early-stage non-small cell lung cancer (NSCLC) patients.Experimental Design: This is a single-arm chemotherapy plus phased ipilimumab phase II study of 24 treatmen ... Full text Link to item Cite

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · December 2017 Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specif ... Full text Link to item Cite

Overcoming obstacles in the design of cancer anorexia/weight loss trials.

Journal Article Crit Rev Oncol Hematol · September 2017 Most advanced cancer patients suffer loss of appetite (anorexia) and loss of weight. Despite the fact that cancer anorexia and weight loss are associated with a poor prognosis and detract from quality of life, no interventions have been demonstrated to pal ... Full text Link to item Cite

Patterns of Failure After Surgery for Non-Small-cell Lung Cancer Invading the Chest Wall.

Journal Article Clin Lung Cancer · July 2017 INTRODUCTION: The patterns of failure after resection of non-small-cell lung cancer (NSCLC) invading the chest wall are not well documented, and the role of adjuvant radiation therapy (RT) is unclear, prompting the present analysis. MATERIALS AND METHODS: ... Full text Link to item Cite

Developments in Molecular Testing and Biosimilars.

Journal Article J Natl Compr Canc Netw · June 2017 Molecular testing and biosimilars offer the potential for increased access to targeted treatment options and reduction in healthcare costs, but come with significant challenges in ensuring patient access to innovation in cancer care while maintaining safe, ... Full text Link to item Cite

A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.

Conference Journal of Clinical Oncology · May 20, 2017 9054 Background: Lung-MAP (S1400) is a National Clinical Trials Network “umbrella” trial for previously-treated SqNSCLC. Sub-study S1400B included patients (pts) with tumors harboring PI3K mutations.Taselisib (GDC-0032), a potent ... Full text Cite

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).

Journal Article J Thorac Oncol · May 2017 INTRODUCTION: The aim of this study was to evaluate efficacy of maintenance sunitinib after first-line chemotherapy for stage IIIB/IV NSCLC. METHODS: Cancer and Leukemia Group B 30607 trial was a randomized, double-blind, placebo-controlled, phase III stud ... Full text Link to item Cite

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

Journal Article Cancer Chemother Pharmacol · March 2017 PURPOSE: To define the maximum tolerated dose (MTD), recommended phase II dose (RPTD), and assess safety and tolerability for the combination of pazopanib plus TH-302, an investigational hypoxia-activated prodrug (HAP), in adult patients with advanced soli ... Full text Link to item Cite

Immune profiling of circulating T cells and TILs following neoadjuvant ipilimumab and chemotherapy in non-small cell lung cancer (NSCLC).

Conference Journal of Clinical Oncology · March 1, 2017 26 Background: Ipilimumab (Ipi) is a humanized CTLA-4 antibody that blocks binding of CTLA-4 to B7, permitting T cell activation through CD28. Phased in Ipi added to chemotherapy (C) may enhance efficacy in NSCLC. Methods: Patien ... Full text Cite

Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.

Journal Article Oncologist · February 2017 PURPOSE: The aim of this study was to investigate whether progression-free survival (PFS) can be considered a surrogate endpoint for overall survival (OS) in malignant mesothelioma. MATERIALS AND METHODS: Individual data were collected from 15 Cancer and L ... Full text Link to item Cite

Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.

Journal Article Cancer Invest · January 2, 2017 The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who unde ... Full text Link to item Cite

ED06.04 Biology and Management of Tumor Cachexia

Conference Journal of Thoracic Oncology · January 2017 Full text Cite

Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.

Journal Article Ann Oncol · October 2016 BACKGROUND: Chemotherapy (CT) combined with radiotherapy is the standard treatment of 'limited-stage' small-cell lung cancer. However, controversy persists over the optimal timing of thoracic radiotherapy and CT. MATERIALS AND METHODS: We carried out a met ... Full text Link to item Cite

Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.

Journal Article Lung Cancer · August 2016 To determine the feasibility and toxicity of radiation therapy, delivered either as definitive treatment or following surgery, following neo-adjuvant immune checkpoint inhibition for locally advanced NSCLC sixteen patients who received neo-adjuvant chemoth ... Full text Link to item Cite

Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).

Journal Article Curr Oncol Rep · June 2016 Muscle wasting in cancer is a common and often occult condition that can occur prior to overt signs of weight loss and before a clinical diagnosis of cachexia can be made. Muscle wasting in cancer is an important and independent predictor of progressive fu ... Full text Link to item Cite

Clinical results in cachexia therapeutics.

Journal Article Curr Opin Clin Nutr Metab Care · May 2016 PURPOSE OF REVIEW: This article highlights recent developments in the area of cancer cachexia and therapeutic interventions. RECENT FINDINGS: Therapeutic interventions in cancer cachexia have been guided by clinical studies focused on the central role of m ... Full text Link to item Cite

Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.

Journal Article Support Care Cancer · April 2016 PURPOSE: Sotatercept may represent a novel approach to the treatment of chemotherapy-induced anemia (CIA). We report the results from two phase 2 randomized studies examining the use of sotatercept for the treatment of CIA in patients with metastatic cance ... Full text Link to item Cite

Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).

Journal Article J Thorac Oncol · March 2016 BACKGROUND: Prophylactic cranial irradiation (PCI) has become a standard option for patients with extensive-stage small cell lung cancer (ES-SCLC). The Cancer and Leukemia Group B 30504 trial was a randomized phase II study of the effect of sunitinib versu ... Full text Link to item Cite

Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma.

Conference Leuk Lymphoma · February 2016 Maintaining high relative dose intensity (RDI) is associated with improved outcomes, especially in patients with aggressive B-cell non-Hodgkin lymphoma (NHL). To evaluate changes in practice, we examined RDI, chemotherapy treatment patterns, dose delays an ... Full text Link to item Cite

Treatment of Lung Cancer in Medically Compromised Patients.

Journal Article Am Soc Clin Oncol Educ Book · 2016 Outcomes for patients with lung cancer have been improved substantially through the integration of surgery, radiation, and systemic therapy for patients with early-stage disease. Meanwhile, advances in our understanding of molecular mechanisms have substan ... Full text Link to item Cite

Cost of Hospitalization in Patients with Cancer and Febrile Neutropenia and Impact of Comorbid Conditions

Conference Blood · December 3, 2015 Background: Febrile neutropenia (FN) remains a serious complication of cancer chemotherapy often leading to hospitalization and an increased risk of mortality and cost.Methods: Data on hospitalizations between 2004 ... Full text Cite

Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups.

Journal Article Lung Cancer · November 2015 PURPOSE: Prognostic models have been proposed to predict survival for non-small-cell lung cancer (NSCLC). It is important to evaluate whether these models perform better than performance status (PS) alone in stage- and age-specific subgroups. PATIENTS AND ... Full text Link to item Cite

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Journal Article J Clin Oncol · October 1, 2015 PURPOSE: To update the 2006 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSFs). METHODS: The American Society of Clinical Oncology convened an Update Committee and conducted a systematic review of ... Full text Link to item Cite

Cachexia

Conference JOURNAL OF THORACIC ONCOLOGY · September 1, 2015 Link to item Cite

Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?

Journal Article Cancer Med · August 2015 This study evaluated the correlation between the risk of febrile neutropenia (FN) estimated by physicians and the risk of severe neutropenia or FN predicted by a validated multivariate model in patients with nonmyeloid malignancies receiving chemotherapy. ... Full text Link to item Cite

The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy.

Journal Article Ann Oncol · July 2015 BACKGROUND: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is associated with higher chemotherapy relative dose intensity, which may lead to improved outcomes; however, the association between G-CSF primary prophylaxis and overall s ... Full text Link to item Cite

Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).

Journal Article J Clin Oncol · May 20, 2015 PURPOSE: To evaluate the efficacy of maintenance sunitinib after chemotherapy for small-cell lung cancer (SCLC). PATIENTS AND METHODS: The Cancer and Leukemia Group B 30504 trial was a randomized, placebo-controlled, phase II study that enrolled patients b ... Full text Link to item Cite

A review of relative dose intensity and survival in patients with metastatic solid tumors.

Journal Article Crit Rev Oncol Hematol · March 2015 Studies have shown that in the curative setting patients with cancer receiving chemotherapy at higher relative dose intensity (RDI) had better clinical outcomes than those receiving treatment at lower RDI. However, the impact of RDI in advanced/metastatic ... Full text Link to item Cite

Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy.

Journal Article Pract Radiat Oncol · 2015 PURPOSE: To assess the efficacy of preoperative positron emission tomography (PET) to stage the ipsilateral hilum in resected non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: All patients who underwent surgery for NSCLC between 1995 and 2008 were ... Full text Link to item Cite

The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study.

Journal Article Springerplus · 2015 BACKGROUND: Febrile neutropenia (FN) is a major dose-limiting toxicity of cancer chemotherapy resulting in considerable morbidity, mortality, and cost. This study evaluated the time course of neutropenic events and patterns of supportive care interventions ... Full text Link to item Cite

Blood utilization and hemoglobin levels in cancer patients after label and coverage changes for erythropoiesis-stimulating agents.

Journal Article Expert Rev Hematol · October 2014 A comprehensive literature search was performed to examine the influence of changes in erythropoietin-stimulating agent (ESA) label and reimbursement policies on utilization of red blood cell transfusions and patient hemoglobin levels in US cancer patients ... Full text Link to item Cite

Tumor acquisition for biomarker research in lung cancer.

Journal Article Cancer Invest · July 2014 The biopsy collection data from two lung cancer trials that required fresh tumor samples be obtained for microarray analysis were reviewed. In the trial for advanced disease, microarray data were obtained on 50 patient samples, giving an overall success ra ... Full text Link to item Cite

Enobosarm and lean body mass in patients with non-small cell lung cancer.

Conference Journal of Clinical Oncology · May 20, 2014 Full text Cite

Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how?

Journal Article J Natl Compr Canc Netw · May 2014 Myeloid growth factors can reduce the risk of chemotherapy-induced neutropenia (CIN) and thus impact the survival of patients with cancer. Patients should be assessed for risk, taking into consideration patient-related risk factors and chemotherapy regimen ... Full text Link to item Cite

Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.

Journal Article Cancer Med · April 2014 Neutropenic complications remain an important dose-limiting toxicity of cancer chemotherapy-associated with considerable morbidity, mortality, and cost. Risk of the initial neutropenic event is greatest during the first cycle. The purpose of this study was ... Full text Link to item Cite

The cause and prevention of anastomotic recurrence following colectomy: An immunohistochemical approach for detecting transforming colonocytes

Journal Article Journal of Cancer · January 1, 2014 With the ability to identify the presence of transforming colonocytes in a field adjacent to an existing primary colon cancer, it is now possible to reduce if not eliminate one of the major causes leading to anastomotic tumor recurrence. In a review of tho ... Full text Cite

A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer.

Journal Article J Thorac Oncol · December 2013 INTRODUCTION: This two-part phase 2 study evaluated the efficacy and safety of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, combined with carboplatin/paclitaxel in patients with previously untreated advanced non-sma ... Full text Link to item Cite

Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.

Journal Article Lung Cancer · December 2013 INTRODUCTION: Standard therapy for limited stage small cell lung cancer (L-SCLC) is concurrent chemotherapy and radiotherapy followed by prophylactic cranial radiotherapy. Predictors of post chemoradiotherapy pulmonary toxicity in limited stage (LS) small ... Full text Link to item Cite

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

Journal Article Ann Oncol · November 2013 BACKGROUND: Talactoferrin alfa is an oral dendritic cell (DC)-mediated immunotherapy (DCMI). We tested whether talactoferrin was superior to placebo in advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: An FORTIS-M trial was an internationa ... Full text Link to item Cite

Abstract C61: Phase I Study of pazopanib in combination with the investigational hypoxia-targeted drug TH-302.

Journal Article Molecular Cancer Therapeutics · November 1, 2013 AbstractBackground: Preclinical data demonstrate anti-VEGF agents can induce hypoxia, which may mediate resistance and induce increased tumor invasiveness. TH-302 is an investigational hypoxia-targeted drug; ... Full text Cite

Moving forward with myeloid growth factors.

Journal Article J Natl Compr Canc Netw · October 1, 2013 Full text Link to item Cite

The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.

Journal Article Ann Oncol · October 2013 BACKGROUND: The granulocyte colony-stimulating factor (G-CSF) is utilized to reduce neutropenic complications in patients receiving cancer chemotherapy. This study represents a systematic review and evidence summary of the impact of G-CSF support on chemot ... Full text Link to item Cite

Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies.

Journal Article J Geriatr Oncol · October 2013 OBJECTIVE: Hospitalized adult patients with cancer and with major comorbidities have higher mortality rates and longer duration of hospitalization. There is limited understanding of risk factors that contribute to prolonged hospitalization and mortality in ... Full text Link to item Cite

Myeloid growth factors.

Journal Article J Natl Compr Canc Netw · October 1, 2013 Febrile neutropenia, a common side effect of myelosuppressive chemotherapy in patients with cancer, can result in prolonged hospitalization and broad-spectrum antibiotic use, often prompting treatment delays or dose reductions of drug regimens. Prophylacti ... Full text Link to item Cite

A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.

Journal Article J Thorac Oncol · August 2013 INTRODUCTION: Standard therapy for limited-stage small-cell lung cancer (L-SCLC) is concurrent chemotherapy and radiotherapy (RT) followed by prophylactic cranial radiotherapy. Although many consider the standard RT regimen to be 45 Gy in 1.5 Gy twice-dail ... Full text Link to item Cite

Prevention and treatment of chemotherapy-induced neutropenia.

Journal Article Clin Adv Hematol Oncol · August 2013 Link to item Cite

A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.

Journal Article Breast Cancer Res Treat · June 2013 Early-stage breast cancer (ESBC) is commonly treated with myelosuppressive chemotherapy, and maintaining full-dose chemotherapy on the planned schedule is associated with improved patient outcome. Retrospective analysis of patients with ESBC treated from 1 ... Full text Link to item Cite

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.

Journal Article Lancet Oncol · June 2013 BACKGROUND: The gold standard endpoint in clinical trials of chemotherapy and radiotherapy for lung cancer is overall survival. Although reliable and simple to measure, this endpoint takes years to observe. Surrogate endpoints that would enable earlier ass ... Full text Link to item Cite

Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.

Journal Article Gynecol Oncol · April 2013 OBJECTIVE: There is limited information concerning the role of relative dose intensity (RDI) on clinical outcomes in solid tumors. The objectives of our study were to evaluate the prognostic significance of RDI and predictors of reduced RDI in women with n ... Full text Link to item Cite

Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.

Journal Article J Clin Oncol · June 10, 2012 PURPOSE: Erlotinib is clinically effective in patients with non-small-cell lung cancer (NSCLC) who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant tumors. We investigated the efficacy of erlotinib alone or in combination with ... Full text Link to item Cite

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.

Journal Article Lung Cancer · June 2012 In anemic patients receiving myelosuppressive chemotherapy, erythropoiesis-stimulating agents (ESAs) raise hemoglobin levels and reduce transfusion requirements, but ESA-related safety concerns exist. To evaluate ESA benefits and risks in lung cancer, we c ... Full text Link to item Cite

Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.

Journal Article Ann Oncol · May 2012 The current third consensus on the systemic treatment of non-small-cell lung cancer (NSCLC) builds upon and updates similar publications on the subject by the Central European Cooperative Oncology Group (CECOG), which has published such consensus statement ... Full text Link to item Cite

Small-cell lung cancer: prognostic factors and changing treatment over 15 years.

Journal Article Clin Lung Cancer · March 2012 BACKGROUND: The incidence of small-cell lung cancer (SCLC) has decreased over several decades. Sixty-eight thousand six hundred eleven patients with SCLC in the National Cancer Data Base (NCDB) were analyzed to describe demographic, treatment, and survival ... Full text Link to item Cite

Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors.

Journal Article Crit Rev Oncol Hematol · February 2012 In this article, we reviewed and quantified reporting of the risk of myelotoxicity, specifically febrile neutropenia (FN), and the related use of supportive care with colony-stimulating factor (CSF) or antibiotics in clinical trials published between Janua ... Full text Link to item Cite

Adjuvant treatment of older patients with lung cancer.

Journal Article Am Soc Clin Oncol Educ Book · 2012 Although advances in the molecular biology of lung cancer have rapidly impacted management of patients with advanced stage non-small cell lung cancer (NSCLC), the principal treatment in the adjuvant setting of early stage NSCLC remains platinum-based chemo ... Full text Link to item Cite

Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.

Journal Article Int J Radiat Oncol Biol Phys · November 15, 2011 PURPOSE: Cancer and Leukemia Group B (CALGB) 30105 tested two different concurrent chemoradiotherapy platforms with high-dose (74 Gy) three-dimensional conformal radiotherapy (3D-CRT) after two cycles of induction chemotherapy for Stage IIIA/IIIB non-small ... Full text Link to item Cite

Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest.

Journal Article J Thorac Oncol · October 2011 INTRODUCTION: Lung cancer is a leading cause of death in the United States and among veterans. This study compares patterns of diagnosis, treatment, and survival for veterans diagnosed with non-small cell lung cancer (NSCLC) using a recently established ca ... Full text Link to item Cite

Myeloid growth factors.

Journal Article J Natl Compr Canc Netw · August 1, 2011 Full text Link to item Cite

PERSISTENT N2 DISEASE AFTER NEOADJUVANT CHEMOTHERAPY-NOW WHAT?

Conference JOURNAL OF THORACIC ONCOLOGY · June 1, 2011 Link to item Cite

Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.

Journal Article Cancer · May 1, 2011 BACKGROUND: A prospective cohort study was undertaken to develop and validate a risk model for neutropenic complications in cancer patients receiving chemotherapy. METHODS: The study population consisted of 3760 patients with common solid tumors or maligna ... Full text Link to item Cite

Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.

Journal Article J Thorac Oncol · February 2011 INTRODUCTION: Voreloxin is an anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, causing double-strand breaks in DNA, irreversible G2 arrest, and rapid onset of apoptosis. Based on preclinical activity of voreloxin in chem ... Full text Link to item Cite

Reply to N. Lathia et al

Journal Article Journal of Clinical Oncology · December 20, 2010 Full text Cite

A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.

Journal Article J Thorac Oncol · October 2010 HYPOTHESIS: Malignant mesotheliomas (MMs) express vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, and cKIT. Sorafenib is a potent inhibitor of the ras/raf/MEK pathway and also targets VEGFR and cKIT. We evaluat ... Full text Link to item Cite

Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.

Journal Article J Clin Oncol · June 10, 2010 PURPOSE: To evaluate the risk of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and overall mortality in patients receiving chemotherapy with or without granulocyte colony-stimulating factor (G-CSF), a systematic review of randomized contro ... Full text Link to item Cite

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?

Journal Article Support Care Cancer · May 2010 Updated international guidelines published in 2006 have broadened the scope for the use of granulocyte colony-stimulating factor (G-CSF) in supporting delivery of myelosuppressive chemotherapy. G-CSF prophylaxis is now recommended when the overall risk of ... Full text Link to item Cite

The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design.

Journal Article BMC Cancer · April 21, 2010 BACKGROUND: The Lung Cancer Exercise Training Study (LUNGEVITY) is a randomized trial to investigate the efficacy of different types of exercise training on cardiorespiratory fitness (VO2peak), patient-reported outcomes, and the organ components that gover ... Full text Open Access Link to item Cite

Age- and sex-specific genomic profiles in non-small cell lung cancer.

Journal Article JAMA · February 10, 2010 CONTEXT: Gene expression profiling may be useful in examining differences underlying age- and sex-specific outcomes in non-small cell lung cancer (NSCLC). OBJECTIVE: To describe clinically relevant differences in the underlying biology of NSCLC based on pa ... Full text Link to item Cite

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.

Journal Article Br J Cancer · January 19, 2010 BACKGROUND: Cancer patients often develop the potentially debilitating condition of anaemia. Numerous controlled studies indicate that erythropoiesis-stimulating agents (ESAs) can raise haemoglobin levels and reduce transfusion requirements in anaemic canc ... Full text Link to item Cite

Erythropoiesis-stimulating agents in older adults with cancer

Chapter · January 1, 2010 Introduction The prevalence of anemia in older persons is higher than in the general population and is associated with significant clinical symptoms and poorer prognosis in this group. An increased incidence of cancer and the use of cytotoxic agents in thi ... Full text Cite

Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.

Journal Article Clin Cancer Res · December 15, 2009 PURPOSE: Cancer cells possess traits reminiscent of those ascribed to normal stem cells. It is unclear whether these phenotypic similarities are the result of a common biological phenotype, such as regulatory pathways. EXPERIMENTAL DESIGN: Lung cancer cell ... Full text Link to item Cite

Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.

Journal Article Cancer · November 15, 2009 BACKGROUND: This prospective study evaluated patient and treatment characteristics that contributed to hematologic toxicity in older breast cancer patients treated with curative intent in the community setting. METHODS: Data were collected on 1224 patients ... Full text Link to item Cite

Management of myelosuppression in the lung cancer patient

Conference JOURNAL OF THORACIC ONCOLOGY · September 1, 2009 Link to item Cite

Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.

Journal Article J Clin Oncol · June 10, 2009 PURPOSE: Although numerous clinical trials have demonstrated the efficacy and tolerability of erythropoiesis-stimulating agents (ESAs) in patients with chemotherapy-induced anemia (CIA), results of some recent trials and one meta-analysis have suggested th ... Full text Link to item Cite

A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer.

Journal Article Am J Clin Oncol · June 2009 INTRODUCTION: Denileukin diftitox, a chimeric protein, uses the cytocidal properties of diphtheria toxin to cells expressing interleukin-2 receptors. The aim of this study was to evaluate the efficacy and safety of denileukin diftitox in the treatment of a ... Full text Link to item Cite

Myeloid growth factors.

Journal Article J Natl Compr Canc Netw · January 2009 Full text Link to item Cite

Cancer diagnostic assessment programs: Standards for the organization of care in Ontario

Journal Article Current Oncology · January 1, 2009 Background: Improving access to better, more efficient, and rapid cancer diagnosis is a necessary component of a high-quality cancer system. How diagnostic services ought to be organized, structured, and evaluated is less understood and studied. Our object ... Cite

An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.

Journal Article Clin Colorectal Cancer · January 2009 PURPOSE: This study evaluated safety, pharmacokinetics, and efficacy of 2 dose schedules and 2 infusion times of panitumumab in patients with advanced solid malignancies. PATIENTS AND METHODS: This phase I multicenter, open-label study sequentially enrolle ... Full text Link to item Cite

Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients: a pilot study.

Journal Article Cancer · December 15, 2008 BACKGROUND: A feasibility study examining the effects of supervised aerobic exercise training on cardiopulmonary and quality of life (QOL) endpoints among postsurgical nonsmall cell lung cancer (NSCLC) patients was conducted. METHODS: Using a single-group ... Full text Link to item Cite

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.

Journal Article Lung Cancer · July 2008 BACKGROUND: Preclinical pharmacological properties of mapatumumab (agonistic human monoclonal antibody to TRAIL-R1) suggest that this antibody reduces cell viability, induces cell death in many types of cancer cell lines in vitro, inhibits or reduces tumor ... Full text Link to item Cite

Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.

Journal Article J Natl Compr Canc Netw · February 2008 This study was undertaken to describe the relationship between the occurrence and timing of neutropenic events and chemotherapy treatment in a community-based population of patients with cancer. The study included 2962 patients with breast, lung, colorecta ... Full text Link to item Cite

Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.

Journal Article Clin Cancer Res · January 15, 2008 PURPOSE: This phase 1 study evaluated the safety, pharmacokinetics, and activity of panitumumab, a fully human, IgG2 monoclonal antibody that targets the epidermal growth factor receptor in patients with previously treated epidermal growth factor receptor- ... Full text Link to item Cite

Cancer supportive care: Advances in therapeutic strategies

Book · January 1, 2008 Written with a broader perspective and knowledge, Cancer Supportive Care: Advances in Therapeutic Strategies presents state-of-the-art management options for the full range of symptoms, toxicities, and complications experienced by cancer patients. In addit ... Cite

Preface

Book · January 1, 2008 Cite

Myeloid growth factors

Chapter · January 1, 2008 The history of the myeloid growth factors parallels the development and evolution of biotechnology over the last several decades. The relationship of neutropenia and infection has been recognized since the advent of myelotoxic chemotherapy and was well des ... Cite

Neutropenia and its complications

Chapter · January 1, 2008 Neutrophils form the first line of host defense from infections by bacterial and fungal pathogens. Whenever there is any break in the integrity of a body surface, it is the capacity to generate an acute inflammatory response with rapid accumulation of neut ... Cite

Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.

Journal Article Cancer · October 1, 2007 BACKGROUND: This prospective study was undertaken to evaluate patient and treatment characteristics that contribute to hematologic toxicity in older cancer patients. METHODS: A nationwide study of 115 community oncology practices was conducted between 2002 ... Full text Link to item Cite

Hitting our stride.

Journal Article Support Cancer Ther · September 1, 2007 Full text Link to item Cite

E10-05: Comprehensive symptom management in advanced lung cancer

Journal Article Journal of Thoracic Oncology · August 2007 Full text Cite

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

Journal Article J Clin Oncol · July 20, 2007 PURPOSE: Randomized controlled trials (RCTs) of prophylactic granulocyte colony-stimulating factors (G-CSF) have demonstrated a significant reduction in febrile neutropenia (FN) after systemic chemotherapy. Several RCTs have been published recently that in ... Full text Link to item Cite

Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.

Journal Article J Clin Oncol · June 20, 2007 PURPOSE: Breast cancer outcomes are worse among black women and women of lower socioeconomic status. The purpose of this study was to investigate racial and social differences in selection of breast cancer adjuvant chemotherapy regimens. METHODS: Detailed ... Full text Link to item Cite

A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.

Journal Article J Thorac Oncol · June 2007 INTRODUCTION: The impact of chemotherapy dose delivery has not been well studied in patients with non-small cell lung cancer (NSCLC). Overlapping hematologic toxicities commonly limit planned dose intensity of combination chemotherapy regimens. A phase II ... Full text Link to item Cite

May day.

Journal Article Support Cancer Ther · May 1, 2007 Full text Link to item Cite

Update on neutropenia and myeloid growth factors.

Journal Article J Support Oncol · April 2007 Link to item Cite

Erythropoietin: high profile, high scrutiny.

Journal Article J Clin Oncol · March 20, 2007 Full text Link to item Cite

A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy.

Journal Article J Thorac Oncol · March 2007 INTRODUCTION: This study evaluated the safety/efficacy of once-weekly (QW) epoetin alfa measured by quality of life (QOL), hemoglobin (Hb), transfusion incidence, tumor response, and survival in patients with chemotherapy-naïve, advanced non-small cell lun ... Full text Link to item Cite

Controlling symptoms in elderly lung cancer patients.

Journal Article J Support Oncol · February 2007 Link to item Cite

Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy.

Journal Article J Clin Oncol · January 20, 2007 PURPOSE: The purpose of this study was to investigate the relationship between socioeconomic status (SES) and the use of intentionally reduced doses of chemotherapy in the adjuvant treatment of breast cancer. PATIENTS AND METHODS: Patients with breast canc ... Full text Link to item Cite

Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.

Journal Article Pharmacoeconomics · 2007 BACKGROUND: The prophylactic use of granulocyte colony-stimulating factors (G-CSFs) reduces the severity and duration of neutropenia and reduces the incidence of febrile neutropenia after cancer chemotherapy. However, the use of G-CSFs, particularly filgra ... Full text Link to item Cite

Cancer management in the era of targeted agents.

Journal Article Support Cancer Ther · January 1, 2007 Full text Link to item Cite

Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.

Journal Article Breast Cancer Res Treat · December 2006 BACKGROUND: This retrospective study was undertaken to define risk factors for reductions in dose intensity of adjuvant chemotherapy in women with early stage breast cancer (ESBC). METHODS: A nationwide survey of 190 community oncology practices was conduc ... Full text Link to item Cite

Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

Journal Article J Clin Oncol · November 1, 2006 PURPOSE: To evaluate the efficacy and toxicity of bortezomib +/- docetaxel as second-line therapy in patients with relapsed or refractory advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients were randomly assigned to bortezomib 1.5 m ... Full text Link to item Cite

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

Journal Article Eur J Cancer · October 2006 Chemotherapy-induced neutropenia is not only a major risk factor for infection-related morbidity and mortality, but is also a significant dose-limiting toxicity in cancer treatment. Patients developing severe (grade 3/4) or febrile neutropenia (FN) during ... Full text Link to item Cite

Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.

Journal Article Int J Radiat Oncol Biol Phys · October 1, 2006 PURPOSE: Thalidomide has broad anticytokine properties, which might protect normal tissues in patients undergoing chemoradiotherapy. The purpose of this study was to determine the maximal tolerated dose of thalidomide when used in combination with vinorelb ... Full text Link to item Cite

Disease management and patient-reported outcomes.

Journal Article Support Cancer Ther · October 1, 2006 Full text Link to item Cite

Targeting anemia in patients with lung cancer.

Journal Article J Thorac Oncol · September 2006 Anemia is highly prevalent in patients with lung cancer, often occurring at baseline and frequently exacerbated as a result of treatment with platinum-based chemotherapy. Anemia has been shown to have a negative effect on quality of life in patients with l ... Link to item Cite

Support for supportive cancer therapy.

Journal Article Support Cancer Ther · July 1, 2006 Full text Link to item Cite

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Journal Article J Clin Oncol · July 1, 2006 PURPOSE: To update the 2000 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSF). UPDATE METHODOLOGY: The Update Committee completed a review and analysis of pertinent data published from 1999 through ... Full text Link to item Cite

Erythropoiesis-stimulating protein support and survival.

Journal Article Oncology (Williston Park) · July 2006 Anemia is common in many patients with cancer treated with chemotherapy. One option for managing chemotherapy-induced anemia (CIA) is erythropoiesis-stimulating proteins (ESPs), which are indicated for the treatment of CIA in patients with most types of ca ... Link to item Cite

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Journal Article Cancer · May 15, 2006 BACKGROUND: Hospitalization for febrile neutropenia (FN) in cancer patients is associated with considerable morbidity, mortality, and cost. The study was undertaken to better define mortality, length of stay (LOS), cost, and risk factors associated with mo ... Full text Link to item Cite

Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.

Journal Article Oncology (Williston Park) · April 2006 Neutropenia is the primary dose-limiting toxicity in patients with cancer treated with systemic chemotherapy. The risk of febrile neutropenia (FN) has been estimated on the basis of the chemotherapy regimen, but studies are now finding a number of patient- ... Link to item Cite

Becoming a supportive cancer therapy generalist.

Journal Article Support Cancer Ther · April 1, 2006 Full text Link to item Cite

Myelotoxicity from chemotherapy.

Journal Article Semin Oncol · February 2006 Myelosuppression continues to be a major dose-limiting toxicity for most chemotherapy regimens. While the development of growth factors has changed the approach to myelosuppression, costs remain high and can be measured both in terms of quality of life (QO ... Full text Link to item Cite

A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.

Journal Article Clin Drug Investig · 2006 OBJECTIVE: To determine the feasibility and maximum tolerated dose of dose-dense topotecan as induction chemotherapy before standard therapy (carboplatin plus etoposide alone or in combination with radiotherapy) in patients with small cell lung cancer (SCL ... Full text Link to item Cite

Integrating support into cancer therapy.

Journal Article Support Cancer Ther · January 1, 2006 Full text Link to item Cite

Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.

Journal Article Clin Lung Cancer · November 2005 BACKGROUND: Almost 70% of all patients with lung cancer in the United States are>65 years of age, and the incidence of small-cell lung cancer (SCLC) increases with age until the eighth decade of life. However, elderly patients are underrepresented in clini ... Full text Link to item Cite

Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.

Journal Article Curr Hematol Rep · November 2005 Neutropenia is a frequent dose-limiting complication of chemotherapy. Although myeloid growth factors decrease the risk of febrile neutropenia and the resulting complications of hospitalizations, dose delays, and dose reductions, not all patients need or b ... Link to item Cite

Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia.

Journal Article Support Cancer Ther · October 1, 2005 BACKGROUND: A phase III study of filgrastim as an adjunct to combination chemotherapy in previously untreated patients with limited- or extensive-stage small-cell lung cancer was conducted. This final analysis explores baseline factors that might predict f ... Full text Link to item Cite

Year three of supportive cancer therapy.

Journal Article Support Cancer Ther · October 1, 2005 Full text Link to item Cite

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

Journal Article J Natl Cancer Inst · July 20, 2005 To determine the accuracy with which Medicare claims data measure chemotherapy use in elderly Medicare beneficiaries with cancer, we performed a criterion validation study. We compared gold-standard clinical trial data for 175 elderly cancer patients treat ... Full text Link to item Cite

A combined analysis of average relative dose intensity in the chemotherapy of solid tumors with pegfilgrastim or filgrastim support.

Journal Article Support Cancer Ther · July 1, 2005 A metaanalysis of 4 clinical studies that treated adult solid tumors with standard combination chemotherapy and growth factor support was conducted to study average relative dose intensity. All studies compared pegfilgrastim with filgrastim in a randomized ... Full text Link to item Cite

Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer.

Journal Article Clin Cancer Res · July 1, 2005 Over the last two decades, several approaches to multimodality therapy have been investigated in patients with advanced unresectable non-small cell lung cancer. These include induction chemotherapy and concurrent chemoradiotherapy. Both approaches have bee ... Full text Link to item Cite

Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base.

Journal Article Clin Lung Cancer · May 2005 The standard treatment of limited-stage small-cell lung cancer (LS-SCLC) has changed over the past 15 years. Standard treatment for LS-SCLC currently involves multiple-agent chemotherapy and early concurrent thoracic radiation therapy. Four patient cohorts ... Full text Link to item Cite

Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

Journal Article J Clin Oncol · April 20, 2005 PURPOSE: To determine whether BMS-275291, a broad-spectrum matrix metalloproteinase inhibitor (MMPI), added to systemic chemotherapy improved survival in advanced non-small-cell lung cancer (NSCLC). In early phase studies, BMS- 275291 was not associated wi ... Full text Link to item Cite

Exploring the breadth of supportive cancer care issues.

Journal Article Support Cancer Ther · January 1, 2005 Full text Link to item Cite

Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.

Journal Article Value Health · 2005 OBJECTIVES: Febrile neutropenia (FN) in patients with cancer treated with chemotherapy has traditionally been managed with inpatient broad-spectrum antibiotics until the infection and neutropenia have resolved. A newer strategy is outpatient oral or intrav ... Full text Link to item Cite

Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?

Journal Article Int J Radiat Oncol Biol Phys · January 1, 2005 PURPOSE: To assess the incidence of clinically significant bronchial stenosis in patients treated with high doses (i.e., >70 Gy) of twice-daily external beam radiation therapy (RT). METHODS AND MATERIALS: The outcomes of 103 patients with unresectable non- ... Full text Link to item Cite

The importance of chemotherapy dose intensity in lung cancer.

Journal Article Semin Oncol · December 2004 The evidence for the importance of maintaining full dose on schedule chemotherapy for lung cancer varies considerably by histologic type. Several studies have evaluated chemotherapy dose and dose intensity in small cell lung cancer; fewer studies have eval ... Full text Link to item Cite

First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study.

Conference Blood · November 16, 2004 AbstractIntroduction: Myelosuppression represents the major dose-limiting toxicity of cancer chemotherapy. This prospective, nationwide study was undertaken to better define risk of neutropenia and its compl ... Full text Cite

Validation of a Risk Model for Hospitalized Adult Cancer Patients with Febrile Neutropenia.

Conference Blood · November 16, 2004 AbstractIntroduction: Febrile neutropenia (FN) represents the most common dose-limiting toxicity associated with systemic chemotherapy and is associated with considerable morbidity and mortality. The majorit ... Full text Cite

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

Journal Article J Clin Oncol · November 1, 2004 PURPOSE: To assess the incidence of and risk factors for reduced relative dose-intensity (RDI) in patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). METHODS: A nationwide survey was conducted of 567 oncology practices with data ... Full text Link to item Cite

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

Journal Article J Clin Oncol · November 1, 2004 PURPOSE: To prospectively determine the maximum-tolerated dose of accelerated hyperfractionated conformal radiotherapy (RT; 1.6 Gy bid) for unresectable locally advanced lung cancer (IIB to IIIA/B) following induction carboplatin/paclitaxel (C/T) or carbop ... Full text Link to item Cite

Year two for supportive cancer therapy.

Journal Article Support Cancer Ther · October 1, 2004 Full text Link to item Cite

One year of supportive cancer therapy.

Journal Article Support Cancer Ther · July 1, 2004 Full text Link to item Cite

Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity.

Journal Article Ann Oncol · July 2004 BACKGROUND: Combined modality therapy (CMT) is the standard of care for patients with unresectable stage III non-small-cell lung cancer (NSCLC); however, insufficient data are available regarding prognostic factors in this disease setting. PATIENTS AND MET ... Full text Link to item Cite

Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.

Journal Article Ann Oncol · March 2004 BACKGROUND: To evaluate the activity and tolerability of gemcitabine plus irinotecan or docetaxel as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Eligible patients with chemotherapy-naïve stage IIIB or IV N ... Full text Link to item Cite

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.

Journal Article Int J Radiat Oncol Biol Phys · March 1, 2004 The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein, with an extracellular ligand-binding domain and intracellular tyrosine kinase domain. Ligand binding induces EGFR dimerization and autophosphorylation on several tyrosine residues ... Full text Link to item Cite

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.

Journal Article Cancer · January 15, 2004 Cytotoxic chemotherapy suppresses the hematopoietic system, impairing host protective mechanisms and limiting the doses of chemotherapy that can be tolerated. Neutropenia, the most serious hematologic toxicity, is associated with the risk of life-threateni ... Full text Link to item Cite

Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.

Journal Article J Clin Oncol · December 15, 2003 PURPOSE: This retrospective study was undertaken to assess practice patterns in adjuvant chemotherapy for early-stage breast cancer (ESBC) and to define the incidence and predictive factors of reduced relative dose-intensity (RDI). PATIENTS AND METHODS: A ... Full text Link to item Cite

Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.

Journal Article Leuk Lymphoma · December 2003 We sought to identify risk factors associated with the time to febrile neutropenia in patients with intermediate-grade, non-Hodgkin's lymphoma (NHL) who were receiving treatment with CHOP chemotherapy. Data were collected from 12 community and academic onc ... Full text Link to item Cite

Delivering optimal adjuvant chemotherapy in primary breast cancer: The role of rHuG-CSF

Journal Article European Journal of Cancer Supplement · November 1, 2003 Most patients with operable breast cancer now receive postoperative medical treatment in the form of adjuvant chemotherapy, hormone manipulation or both. These additional interventions have led to a significant improvement in disease-free survival and over ... Full text Cite

Expanding the horizons of supportive therapy.

Journal Article Support Cancer Ther · October 1, 2003 Full text Link to item Cite

Small-cell lung cancer: a review of clinical trials.

Journal Article Semin Thorac Cardiovasc Surg · October 2003 Small-cell lung cancer (SCLC) is expected to account for 25% of the approximate 170,000 cases of lung cancer diagnosed in the United States in 2002. Although sensitive and responsive to chemotherapy, SCLC has an increased propensity for early metastases, w ... Full text Link to item Cite

Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.

Journal Article Semin Oncol · August 2003 Filgrastim (r-metHuG-CSF) was approved in the United States in 1991 for use in decreasing the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies treated with myelosuppressive chemotherapy. Colony-stimulat ... Full text Link to item Cite

Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.

Journal Article Pharmacotherapy · August 2003 The major dose-limiting toxicity associated with myelosuppressive chemotherapy is neutropenia, which can be ameliorated with proactive administration of granulocyte colony-stimulating factor (G-CSF). Pegfilgrastim is a long-acting G-CSF, recently approved ... Full text Link to item Cite

Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy.

Journal Article Int J Radiat Oncol Biol Phys · July 15, 2003 PURPOSE: To report the incidence of late complications in long-term survivors of very-high-dose thoracic radiotherapy (RT) treated on a prospective clinical trial. METHODS AND MATERIALS: Patients with locally advanced or medically inoperable non-small-cell ... Full text Link to item Cite

Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials.

Journal Article J Natl Compr Canc Netw · July 2003 Delivery of cancer chemotherapy is often limited by myelotoxicity, primarily neutropenia. As part of an effort to create a model to predict the risk of chemotherapy-induced neutropenia, we reviewed the reports of randomized clinical trials with more than 5 ... Full text Link to item Cite

Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer.

Journal Article Int J Radiat Oncol Biol Phys · June 1, 2003 PURPOSE: To review the outcome of patients with limited-stage small-cell lung cancer receiving daily thoracic irradiation (RT) to approximately 60 Gy. METHODS AND MATERIALS: The records of patients treated with RT for limited-stage small-cell lung cancer b ... Full text Link to item Cite

MEMS 3D optical mirror/scanner

Conference Proceedings International Conference on MEMS Nano and Smart Systems Icmens 2003 · January 1, 2003 This paper presents a novel MEMS optical mirror based on a proprietary fabrication process. The mirror is fabricated with single crystal silicon and has hexagonal reflective surface 600 μm across, with a measured surface roughness is less than 20 angstroms ... Full text Cite

New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.

Journal Article J Natl Compr Canc Netw · January 2003 Advances in chemotherapy and multimodality treatments of patients with non-small-cell lung cancer (NSCLC) have improved outcomes for these patients over the past decade. Unfortunately, gains have been modest, and new therapeutic strategies are eagerly awai ... Link to item Cite

Activation of tyrosine kinases in cancer.

Journal Article Oncologist · 2003 Receptor and nonreceptor tyrosine kinases (TKs) have emerged as clinically useful drug target molecules for treating certain types of cancer. Epidermal growth factor receptor (EGFR)-TK is a transmembrane receptor TK that is overexpressed or aberrantly acti ... Full text Link to item Cite

Anemia and lung cancer.

Journal Article Lung Cancer · December 2002 Full text Link to item Cite

Pegfilgrastim for the prevention of chemotherapy-induced neutropenic complications, with dosing once per chemotherapy cycle

Journal Article Today S Therapeutic Trends · December 1, 2002 In the past 10 years, colony-stimulating factors (CSFs) such as filgrastim have been used successfully to reduce the clinical impact of chemotherapy-induced neutropenia. The recent availability of pegfilgrastim (Neulasta™), a next-generation pegylated filg ... Cite

Neutrophil growth factors.

Journal Article Curr Hematol Rep · November 2002 A significant advance in the field of neutrophil growth factors has occurred with the commercial availability of pegfilgrastim (Neulasta, Amgen, Thousand Oaks, CA), a new-generation, pegylated filgrastim molecule with a sustained duration of action. Pegyla ... Link to item Cite

Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.

Journal Article J Clin Oncol · October 15, 2002 PURPOSE: To evaluate new drugs in combination with cisplatin in unresectable stage III non-small-cell lung cancer, Cancer and Leukemia Group B (CALGB) conducted a randomized phase II study of two cycles of induction chemotherapy followed by two additional ... Full text Link to item Cite

Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.

Journal Article Clin Cancer Res · September 2002 PURPOSE: The purpose of the study is to investigate the tolerability of interleukin 2 (IL-2) after intensive chemotherapy in elderly acute myeloid leukemia (AML) patients in first complete remission (CR). EXPERIMENTAL DESIGN: AML patients > or =60 years in ... Link to item Cite

Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials.

Journal Article Cancer · September 1, 2002 BACKGROUND: Prior research has documented the under-representation in clinical trials of older patients with cancer. In part of a larger study to test the magnitude of these barriers to entering eligible older patients with carcinoma of the breast into cli ... Full text Link to item Cite

Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence.

Journal Article Oncology (Williston Park) · September 2002 The clinical development of recombinant human erythropoietin (rHuEPO) has had a remarkable impact on the clinical practice of oncology. A decade ago, randomized, placebo-controlled trials in anemic cancer patients demonstrated that rHuEPO resulted in an im ... Link to item Cite

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.

Journal Article Cancer · August 15, 2002 BACKGROUND: Hemoglobin increases have been associated with quality of life (QOL) improvements in anemic cancer patients treated with epoetin alfa, but intervention generally has been reserved for symptomatic anemia or hemoglobin < 10 g/dL. Relationships am ... Full text Link to item Cite

Clinical uses of pegylated pharmaceuticals in oncology.

Journal Article Cancer Treat Rev · April 2002 A number of agents that are used in the treatment of cancer have a suboptimal pharmacokinetic profile that necessitates prolonged or repetitive administration. Pegylation of these agents may help overcome these shortcomings without compromising the agents' ... Full text Link to item Cite

Clinical benefits of epoetin alfa therapy in patients with lung cancer.

Journal Article Clin Lung Cancer · February 2002 A retrospective subset analysis of anemic lung cancer patients who participated in three large, multicenter, community-based studies of 3-times-weekly (TIW) or once-weekly (QW) recombinant human erythropoietin (r-HuEPO, epoetin alfa) as an adjunct to chemo ... Full text Link to item Cite

Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.

Journal Article Drugs · 2002 Neutropenia is a common and potentially dangerous adverse effect of cancer chemotherapy. It also often necessitates a reduction or delay in dose, thus compromising efficacy. The human granulocyte colony-stimulating factor filgrastim has been proven to have ... Full text Link to item Cite

Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation.

Journal Article J Clin Oncol · September 1, 2001 PURPOSE: The ability to prescribe treatment based on relative risks for normal tissue injury has important implications for oncologists. In non-small-cell lung cancer, increasing the dose of radiation may improve local control and survival. Changes in plas ... Full text Link to item Cite

Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung cancer.

Journal Article Clin Lung Cancer · February 2001 The purpose of this study was to examine the safety and efficacy of carboplatin/etoposide/paclitaxel in patients with untreated stage IV non-small-cell lung cancer (NSCLC) and extensive small-cell lung cancer (SCLC). Carboplatin was administered intravenou ... Full text Link to item Cite

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

Journal Article Oncologist · 2001 The maximum tolerated dose of conformal radiation therapy delivered at 1.6 Gy bid is being assessed in patients with unresectable stage IIB-IIIB non-small cell lung cancer who have been treated with induction regimens consisting of carboplatin plus paclita ... Full text Link to item Cite

Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.

Journal Article J Clin Oncol · July 2000 PURPOSE: To explore the use of SD/01 (a polyethylene glycol-conjugated filgrastim shown in preclinical studies to have a prolonged half-life) in patients with chemotherapy-induced neutropenia. PATIENTS AND METHODS: Thirteen patients with non-small-cell lun ... Full text Link to item Cite

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

Journal Article J Clin Oncol · June 2000 PURPOSE: To confirm the promising phase II results of docetaxel monotherapy, this phase III trial was conducted of chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC) who had previously failed platinum-containing chemotherapy. PATIEN ... Full text Link to item Cite

Gene therapy for lung cancer.

Journal Article Clin Lung Cancer · February 2000 Gene therapy is emerging as a promising modality for the treatment of lung cancer. Diverse strategies employing gene therapy for lung cancer have been investigated in vitro and in animal models, and a number of these approaches have met with promising resu ... Full text Link to item Cite

Stem cell factor

Chapter · January 1, 2000 I. INTRODUCTION Efforts to understand mutations in inbred laboratory mice leading to abnormalities of coat color, hematopoiesis, and fertility began 4 decades ago and were ultimately explained after the characterization of stem cell factor (SCF) and its re ... Cite

Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy.

Journal Article Cytokines Cell Mol Ther · December 1999 Mucositis, the inflammation and necrosis of mucosal membranes, is a serious and debilitating consequence of many cancer therapies. We were interested in the potential role of filgrastim (recombinant methionyl human granulocyte colony-stimulating factor, r- ... Link to item Cite

Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.

Journal Article Pharmacoeconomics · November 1999 OBJECTIVE: To measure the cost effectiveness of a supportive care intervention when the no-treatment option is unrealistic in an analysis of recombinant human erythropoietin (epoetin) treatment for anaemic patients with cancer undergoing chemotherapy. Furt ... Full text Link to item Cite

Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.

Journal Article J Clin Oncol · September 1999 PURPOSE: To evaluate the antitumor efficacy and safety of a combination of irinotecan (CPT-11) and cisplatin in patients with inoperable non-small-cell lung cancer (NSCLC). A secondary objective was to characterize the pharmacokinetics and pharmacodynamics ... Full text Link to item Cite

Hematopoietic growth factors in cancer chemotherapy.

Journal Article Cancer Chemother Biol Response Modif · 1999 Hematopoietic growth factors have made a significant impact on the treatment of cancer, primarily in the prevention of infections associated with chemotherapy-induced neutropenia, in progenitor cell transplantation, in chemotherapy-induced thrombocytopenia ... Link to item Cite

Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care: Recombinant Human Erythropoietin as a Treatment of Cancer-Associated Anaemia

Journal Article PharmacoEconomics · 1999 Objective: To measure the cost effectiveness of a supportive care intervention when the no-treatment option is unrealistic in an analysis of recombinant human erythropoietin (epoetin) treatment for anaemic patients with cancer undergoing chemotherapy. Furt ... Cite

Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.

Journal Article Semin Oncol · October 1998 Neutropenia is the most common dose-limiting toxicity of conventional chemotherapy. The colony-stimulating factors (CSFs), granulocyte (G)-CSF and granulocyte-macrophage (GM)-CSF, stimulate proliferation and maturation of myeloid progenitors and have been ... Link to item Cite

A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.

Journal Article J Interferon Cytokine Res · August 1998 A previous phase II study (CALGB 9132) of etoposide/cisplatin + rG-CSF in patients with advanced non-small cell lung cancer (NSCLC) showed a marked difference in the absolute neutrophil count (ANC) nadirs between courses 1 and 2. Median ANC nadirs for cour ... Full text Link to item Cite

Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.

Journal Article Oncology (Williston Park) · August 1998 During the 1980s, platinum-based regimens were yielding response rates typically less than 25%, median survival durations of about 25 weeks, and 1-year survival rates less than 25% in patients with advanced non-small-cell lung cancer (NSCLC). Currently, re ... Link to item Cite

Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin.

Journal Article Am J Clin Oncol · August 1998 Tumor lysis syndrome, characterized by multiple metabolic abnormalities resulting from abrupt tumor cell death and release of intracellular constituents and metabolites, is most commonly associated with the treatment of highly chemotherapy-sensitive lympho ... Full text Link to item Cite

Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly.

Journal Article Am J Med · May 1998 PURPOSE: To determine if there is an increased prevalence of monoclonal gammopathy in elderly blacks compared with whites, analogous to the difference in incidence of multiple myeloma reported for the two racial groups and to confirm age and gender relatio ... Full text Link to item Cite

Vinorelbine and Carboplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer

Journal Article Oncology · December 1, 1997 Greenville Cancer Center Greenville, South Carolina Randomized trials in patients with advanced non-small-cell lung cancer (NSCLC) have demonstrated that the combination of vinorelbine (Navelbine) and cisplatin (Platinol), compared with vinorelbine alone, ... Cite

The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy.

Journal Article Ann Oncol · November 1997 BACKGROUND: A phase 2 trial was done to study effects of varying treatment schedule of Filgrastim (r-metHuG-CSF) on hematologic recovery following chemotherapy. PATIENTS AND METHODS: Forty-six patients with extensive small-cell carcinoma of the lung were r ... Full text Link to item Cite

A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer

Journal Article Seminars in Oncology · October 22, 1997 We initiated a phase II pilot study to determine whether adding paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to combination carboplatin/etoposide is tolerable and active in patients with advanced non-small cell lung cancer and extensive ... Cite

Docetaxel/vinorelbine combination therapy in non-small-cell lung cancer

Journal Article Oncology · August 27, 1997 Docetaxel (Taxotere) has demonstrated significant activity as a single agent in the treatment of patients with advanced non-small-cell lung cancer. Projected median survival in both previously untreated and treated patients is reported to be 9 months. In a ... Cite

A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer.

Journal Article Semin Oncol · August 1997 We initiated a phase II pilot study to determine whether adding paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to combination carboplatin/etoposide is tolerable and active in patients with advanced non-small cell lung cancer and extensive ... Link to item Cite

Safety of concomitant use of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor with cytotoxic chemotherapy agents.

Journal Article Curr Opin Hematol · May 1997 Most studies that use recombinant granulocytopoietic cytokines, such as granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), with the intent of attenuating neutropenia generally have delayed the admin ... Full text Link to item Cite

Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.

Journal Article N Engl J Med · February 6, 1997 BACKGROUND: Polyethylene glycol (PEG)-conjugated recombinant human megakaryocyte growth and development factor (MGDF, also known as PEG-rHuMGDF), a recombinant molecule related to thrombopoietin, specifically stimulates megakaryopoiesis and platelet produc ... Full text Link to item Cite

Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).

Journal Article Am J Clin Oncol · February 1997 The maximum tolerated dose (MTD) of etoposide and carboplatin without growth factor support was previously defined by Cancer and Leukemia Group B (CALGB) as 200 and 125 mg/m2/day x 3, respectively, given every 28 days to previously untreated patients who h ... Full text Link to item Cite

Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer.

Journal Article J Clin Oncol · October 1996 PURPOSE: This prospective randomized trial was performed to compare the effectiveness of intravenous vinorelbine tartrate with intravenous fluorouracil and leucovorin (5-FU/LV) on the primary end points of survival, quality of life (QOL), and relief of can ... Full text Link to item Cite

A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.

Journal Article Lung Cancer · June 1996 This Phase II study was designed to determine the efficacy of two chemotherapy regimens with G-CSF support for patients with advanced non-small cell lung cancer (NSCLC). One-hundred and one patients with Stage IIIB or IV NSCLC and performance status 0-1 we ... Full text Link to item Cite

Ambulatory sclerotherapy for malignant pleural effusions.

Journal Article Radiology · April 1996 PURPOSE: To determine the feasibility of ambulatory drainage and sclerotherapy in malignant pleural effusions. MATERIALS AND METHODS: Nineteen consecutive patients with symptomatic malignant pleural effusions were enrolled. None of the patients previously ... Full text Link to item Cite

Update: vinorelbine (navelbine) in non-small cell lung cancer.

Journal Article Semin Oncol · April 1996 Vinorelbine (navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France), a novel semisynthetic vinca alkaloid, is the first drug approved by the Food and Drug Administration in over 20 years for the first-line tre ... Link to item Cite

Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients.

Journal Article J Am Acad Dermatol · October 1995 BACKGROUND: Recombinant human stem-cell factor (SCF), a cytokine acting on hematopoietic progenitor cells, has potential for the treatment of several hematologic and oncologic disorders. In a hematology-oncology phase I trial of SCF, several patients had c ... Full text Link to item Cite

The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.

Journal Article Semin Oncol · June 1995 The ifosfamide/carboplatin/etoposide (ICE) combination represents an active chemotherapy regimen across a wide variety of disease types. The most common limiting toxicity for all three of these agents individually and in combination is myelosuppression. Th ... Link to item Cite

Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor.

Journal Article Semin Oncol · October 1994 Treatment with platinum agents or the new vinca alkaloid vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France) results in prolonged survival in patients with advanced non-small cell lung cancer ( ... Link to item Cite

Vinorelbine (Navelbine) in non-small cell lung cancer: future directions.

Journal Article Semin Oncol · October 1994 Randomized clinical trials of vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France) as a single agent and in combination with cisplatin have demonstrated antitumor activity in patients with advan ... Link to item Cite

Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer.

Journal Article Cancer · August 15, 1994 BACKGROUND: The purpose of this study was to assess the ability of administering to patients induction chemotherapy with carboplatin and etoposide (VP-16), followed by full-course radiation therapy and weekly carboplatin with tolerable toxicity as preopera ... Full text Link to item Cite

A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease.

Journal Article Cancer · July 1, 1994 BACKGROUND: Advanced stage Hodgkin's disease (HD) usually is treated with combination chemotherapy with or without supplemental irradiation. The risk of significant acute and long term toxicity when the chemotherapy regimen contains alkylating agents has p ... Full text Link to item Cite

Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale.

Journal Article Cancer · April 15, 1994 BACKGROUND: This study continued the development and psychometric testing of the Lung Cancer Symptom Scale (LCSS), a disease- and site-specific instrument primarily measuring the physical and functional dimensions of quality of life for individuals with lu ... Full text Link to item Cite

Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer

Journal Article Clinical Infectious Diseases · January 1, 1994 Patients with small-cell lung cancer were enrolled in a multicenter, randomized, double-blind, placebo-controlled trial of recombinant methionyl G-CSF to study the incidence of infection as manifested by fever with neutropenia (absolute neutrophil count,<1 ... Full text Cite

Stem cell factor is a potent synergistic factor in hematopoiesis.

Journal Article Oncology · 1994 Stem cell factor (SCF), a ligand for c-kit, has a broad range of activities including effects on cells at or near the level of the multipotential stem cell as well as on committed cells. Preclinical studies show that SCF can protect against lethal irradiat ... Full text Link to item Cite

Lung cancer in North Carolina.

Journal Article N C Med J · July 1993 Link to item Cite

Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.

Journal Article J Clin Oncol · July 1993 PURPOSE: The primary objective of this randomized prospective study was to compare the survival of limited-stage small-cell lung cancer (SCLC) patients treated with chemotherapy alone or chemotherapy plus thoracic radiotherapy (TRT). A secondary objective ... Full text Link to item Cite

Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma.

Journal Article Leuk Lymphoma · 1993 Idarubicin, a new analogue of daunorubicin, was administered intravenously at a dose of 15 mg/m2 to 31 patients with previously treated patients with unfavorable non-Hodgkin's lymphoma. Clinical characteristics included median age 69 years, performance sta ... Full text Link to item Cite

Long‐term results of combined modality therapy for esophageal cancer

Journal Article Radiation Oncology Investigations · January 1, 1993 Published local control and survival rates strongly suggest the superiority of concurrent chemotherapy (CT) and radiotherapy (RT) over RT alone in the management of esophageal cancer, at least in the first 2–3 years after treatment. It is not yet known, ho ... Full text Cite

A comparative study of monoclonal gammopathies and immunoglobulin levels in Japanese and United States elderly.

Journal Article J Am Geriatr Soc · January 1993 OBJECTIVE: To define the prevalence of monoclonal immunoglobulin (Ig) proteins and quantitative serum immunoglobulin levels in elderly Japanese in comparison with elderly Caucasians as possible factors related to the reported lower incidence of multiple my ... Full text Link to item Cite

The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.

Journal Article Eur J Cancer · 1993 The objective of the study was to estimate the net impact on health resource utilisation of using recombinant granulocyte colony-stimulating factor (filgrastim) following myelosuppressive chemotherapy. Cost minimisation of the study medication in a randomi ... Full text Link to item Cite

Carboplatin, etoposide, and radiotherapy, followed by surgery, for the treatment of marginally resectable non-small cell lung cancer.

Journal Article Cancer Treat Rev · 1993 The present study was undertaken in order to determine the feasibility and efficacy of induction chemotherapy with carboplatin and etoposide, followed by weekly carboplatin and full-course radiotherapy as pre-operative therapy for marginally resectable non ... Full text Link to item Cite

Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma.

Journal Article Cancer Res · July 15, 1992 Idarubicin, a new analogue of daunorubicin, was administered i.v. at a dose of 15 mg/m2 to 31 previously treated patients with unfavorable non-Hodgkin's lymphoma. Clinical characteristics included median age, 69 years; performance status, 1; and prior chem ... Link to item Cite

Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.

Journal Article Cancer Res · May 1, 1992 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) resistance may be mediated by repair of chloroethylated guanine before stable cross-linking occurs. Guanine adducts may be repaired by the enzyme O6-alkylguanine-DNA alkyltransferase (O6-AGAT). Such repair irreve ... Link to item Cite

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

Journal Article J Clin Oncol · February 1992 PURPOSE: The trial was undertaken to determine (1) the relative efficacy/toxicity of two commonly used combination chemotherapy regimens in patients with extensive small-cell lung cancer (SCLC) and (2) whether the rapid alternation of these two regimens co ... Full text Link to item Cite

G-CSF for fever and neutropenia induced by chemotherapy.

Journal Article N Engl J Med · January 23, 1992 Link to item Cite

Colony-stimulating factors: clinical applications.

Journal Article Pharmacotherapy · 1992 Recombinant human colony-stimulating factors (CSFs) have potential for wide use in the areas of oncology and infectious disease. Granulocyte CSF and granulocyte-macrophage CSF currently are approved for use in the treatment of neutropenia associated with s ... Link to item Cite

Patterns of failure following combined modality therapy for esophageal cancer, 1984-1990.

Journal Article Int J Radiat Oncol Biol Phys · 1992 From 1984-1990, 143 patients with squamous cell or adenocarcinoma of the esophagus were enrolled in a Phase I/II study of neoadjuvant chemotherapy followed by concurrent chemotherapy plus radiotherapy with or without subsequent esophagectomy. Patients rece ... Full text Link to item Cite

Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

Journal Article N Engl J Med · July 18, 1991 BACKGROUND: Neutropenia and infection are major dose-limiting side effects of chemotherapy. Previous studies have suggested that recombinant methionyl granulocyte colony-stimulating factor (G-CSF) can reduce chemotherapy-related neutropenia in patients wit ... Full text Link to item Cite

Anti-inflammatory effects of pentoxifylline in claudication.

Journal Article Am J Med Sci · February 1991 We measured neutrophil elastase/alpha 1 proteinase inhibitor complex (E/alpha) levels by ELISA in plasma samples drawn from 19 patients with claudication, before and at 1 and 2 months after initiation of pentoxifylline (PTF), 400 mg. p.o. tid. Plasma E/alp ... Full text Link to item Cite

Improved survival in advanced Hodgkin's disease with the use of combined modality therapy.

Journal Article Int J Radiat Oncol Biol Phys · September 1990 To compare the effectiveness of combined modality therapy and chemotherapy alone for the treatment of advanced Hodgkin's disease (Stages IIB-IV), records of 154 patients who achieved a complete or partial response to induction combination chemotherapy were ... Full text Link to item Cite

Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication.

Journal Article J Lab Clin Med · June 1990 We have previously shown that pentoxifylline, a drug used in intermittent claudication, causes depolymerization of actin in leukocytes in vitro. In this study we evaluated several parameters in peripheral blood obtained from 17 patients receiving pentoxify ... Link to item Cite

Correlation between erythrocyte CR1 reduction and other blood proteinase markers in patients with malignant and inflammatory disorders.

Journal Article Blood · April 15, 1990 Erythrocyte CR1, a C3b/C4b-binding complement-regulatory protein, is sensitive to proteolysis in vitro. To test the hypothesis that in vivo erythrocyte CR1 reduction results from intravascular proteinase activities, we used enzyme-linked immunosorbent assa ... Link to item Cite

Development of multiple monoclonal serum immunoglobulins (multiclonal gammopathy) following both HLA-identical unfractionated and T cell-depleted haploidentical bone marrow transplantation in severe combined immunodeficiency.

Journal Article J Clin Immunol · March 1990 We have identified five patients with severe combined immunodeficiency (SCID) who developed multiple monoclonal serum immunoglobulin components (multiclonal gammopathy) following bone marrow transplantation. Four patients received haploidentical bone marro ... Full text Link to item Cite

Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranulation, and superoxide production.

Journal Article J Leukoc Biol · March 1990 The effects of pentoxifylline (Trental) on human neutrophil CR3 up-modulation, degranulation, and superoxide production were studied. We used the chemotactic peptide fMLP and the phorbol ester PMA as soluble stimuli, and beta-glucan particles as a CR3-spec ... Full text Link to item Cite

An in vitro analogue of immune dysfunction with altered immunoglobulin production in the aged.

Journal Article J Am Geriatr Soc · December 1989 The consequences of aging of the immune system include impaired T-lymphocyte responsiveness and aberrant immunoglobulin production. Although T cells from elderly individuals have a well-described defect in lymphoblastic transformation in response to some p ... Full text Link to item Cite

Hodgkin's disease presenting as myelofibrosis.

Journal Article Cancer · October 15, 1989 Four patients with Hodgkin's disease and bone marrow fibrosis are presented in whom the clinical presentation was dominated by cytopenias; this was associated with a delayed diagnosis for an average of 20 months. Despite marrow involvement, chemotherapy re ... Full text Link to item Cite

Actin depolymerization and inhibition of capping induced by pentoxifylline in human lymphocytes and neutrophils.

Journal Article J Cell Physiol · December 1988 Pentoxifylline is used clinically for the treatment of intermittent claudication. It is believed to exert its effect by altering the rheologic properties of blood. The cytoskeleton plays an important role in the maintenance of cell structure and function. ... Full text Link to item Cite

Lung cancer in the elderly.

Journal Article Compr Ther · June 1988 Link to item Cite

Sinus histiocytosis with massive lymphadenopathy. Case report and review of a multisystemic disease with cutaneous infiltrates.

Journal Article J Am Acad Dermatol · June 1988 A report of a patient with the rare syndrome of sinus histiocytosis with massive lymphadenopathy is presented here. This patient is unusual in several respects, including his longevity after diagnosis, the presence of a benign monoclonal gammopathy, and th ... Full text Link to item Cite

Erythrocyte anisocytosis. Visual inspection of blood films vs automated analysis of red blood cell distribution width.

Journal Article Arch Intern Med · April 1988 An improved anemia classification may be available by combining measures of red blood cell size variability with mean corpuscular volume. Visual inspection of the peripheral blood film allows semiquantitative description of anisocytosis while quantitative ... Full text Link to item Cite

Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer.

Journal Article J Clin Oncol · March 1988 From June 1982 through October 1985, the Southeastern Cancer Study Group randomized patients with limited small-cell lung cancer (SCLC) to cyclophosphamide plus doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) plus vincristine (CAV) for six cycle ... Full text Link to item Cite

Lung cancer in the elderly.

Journal Article Clin Geriatr Med · November 1987 Half of all lung cancers occur in persons aged 65 years and older. The symptoms of lung cancer in the elderly may be nonspecific and misleading. Age trends in incidence, histologic subtype, and stage suggest that selective screening of older persons for lu ... Link to item Cite

Relationship of cancer and aging.

Journal Article Clin Geriatr Med · August 1987 The major risk factor for cancer is progressive age. Molecular advances in our understanding of carcinogenesis and the aging process are helping to clarify this relationship. The magnitude of cancer in the elderly warrants institution of an active preventi ... Link to item Cite

Pulmonary hypertension secondary to serum hyperviscosity in a patient with rheumatoid arthritis.

Journal Article Am J Med · May 1987 A patient with rheumatoid arthritis who was evaluated for dyspnea of six months' duration is described. Although no primary cardiac or parenchymal lung disease was identified, right heart catheterization revealed marked pulmonary hypertension. The patient ... Full text Link to item Cite

Clinical utility of erythrocyte sedimentation rate and plasma protein analysis in the elderly.

Journal Article Am J Med · February 1987 The utilization and interpretation of the erythrocyte sedimentation rate in the elderly have been surrounded by controversy and confusion. To improve the understanding of the erythrocyte sedimentation rate and its determinants in the aged, a defined popula ... Full text Link to item Cite

Evaluation of monoclonal gammopathies in the "well" elderly.

Journal Article Am J Med · January 1987 The study of monoclonal gammopathies in the elderly provides an opportunity to define immunologic and neoplastic changes with aging. Previous reports using paper and cellulose acetate electrophoresis have documented an age-related increase in monoclonal ga ... Full text Link to item Cite

Influence of donor-specific blood transfusions on host cellular immune responsiveness

Journal Article Transplantation Proceedings · January 1, 1986 Cite

The essential role of L-glutamine in lymphocyte differentiation in vitro.

Journal Article J Cell Physiol · August 1985 The biochemistry of human B lymphocyte differentiation to plasma cells is incompletely understood. L-glutamine appears to be required for both lymphoblastic transformation and plasma cell formation in pokeweed-mitogen-stimulated human peripheral blood mono ... Full text Link to item Cite

Evaluation of hyperviscosity in monoclonal gammopathies.

Journal Article Am J Med · July 1985 The serum or plasma hyperviscosity syndrome has been described in both monoclonal and polyclonal immunoglobulin disorders. The usefulness of initial and serial plasma viscosity measurements by an automated viscometer technique was evaluated and compared wi ... Full text Link to item Cite

Aging and neoplasia.

Journal Article Annu Rev Gerontol Geriatr · 1984 Link to item Cite